What is Structure Therapeutics Inc ADR's earnings per share (EPS)?

Structure Therapeutics Inc ADR (GPCR) reported diluted earnings per share of $-0.80 for fiscal year 2025. This represents a -2.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Structure Therapeutics Inc ADR Financials

GPCR

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Structure Therapeutics Inc ADR (GPCR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Structure Therapeutics Inc ADR passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.57x

For every $1 of reported earnings, Structure Therapeutics Inc ADR generates $1.57 in operating cash flow (-$222.2M OCF vs -$141.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$175.2M

YoY-11.4%

Structure Therapeutics Inc ADR's EBITDA was -$175.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.4% from the prior year.

Net Income

-$141.2M

YoY-15.2%

Structure Therapeutics Inc ADR reported -$141.2M in net income in fiscal year 2025. This represents a decrease of 15.2% from the prior year.

EPS (Diluted)

$-0.80

YoY-2.6%

Structure Therapeutics Inc ADR earned $-0.80 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 2.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$225.8M

YoY-91.5%

Structure Therapeutics Inc ADR generated -$225.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 91.5% from the prior year.

Cash & Debt

$799.6M

YoY+371.7%

Structure Therapeutics Inc ADR held $799.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

213M

YoY+23.5%

Structure Therapeutics Inc ADR had 213M shares outstanding in fiscal year 2025. This represents an increase of 23.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-9.3%

YoY+4.9pp

Structure Therapeutics Inc ADR's ROE was -9.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$225.3M

YoY+107.0%

Structure Therapeutics Inc ADR invested $225.3M in research and development in fiscal year 2025. This represents an increase of 107.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$3.6M

YoY+180.2%

Structure Therapeutics Inc ADR invested $3.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 180.2% from the prior year.

GPCR Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$225.3M+107.0%	$108.8M+55.2%	$70.1M+93.7%	$36.2M
SG&A Expenses	$61.6M+24.6%	$49.4M+51.2%	$32.7M+99.6%	$16.4M
Operating Income	-$176.6M-11.6%	-$158.2M-54.0%	-$102.8M-95.5%	-$52.6M
Interest Expense	N/A	N/A	N/A	N/A
Income Tax	$515K+66.1%	$310K+31.4%	$236K+1288.2%	$17K
Net Income	-$141.2M-15.2%	-$122.5M-36.7%	-$89.6M-74.6%	-$51.3M
EPS (Diluted)	$-0.80-2.6%	$-0.78+3.7%	$-0.81	$-5.51

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$59.0M+7.8%	$54.7M+27.6%	$42.9M	N/A	$32.6M+47.8%	$22.1M+6.6%	$20.7M
SG&A Expenses	N/A	$14.8M-6.0%	$15.7M+17.1%	$13.4M	N/A	$13.2M+17.5%	$11.3M-0.6%	$11.3M
Operating Income	N/A	-$73.8M-4.7%	-$70.5M-25.1%	-$56.3M	N/A	-$45.8M-37.6%	-$33.3M-4.1%	-$32.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$108K-22.3%	$139K+41.8%	$98K	N/A	$92K+73.6%	$53K+82.8%	$29K
Net Income	N/A	-$65.7M-6.6%	-$61.7M-31.7%	-$46.8M	N/A	-$34.0M-30.5%	-$26.0M0.0%	-$26.0M
EPS (Diluted)	N/A	$-0.37	N/A	$-0.27	N/A	$-0.20-11.1%	$-0.18+5.3%	$-0.19

GPCR Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$1.6B+75.3%	$903.3M+87.4%	$482.0M+392.6%	$97.8M
Current Assets	$1.6B+76.2%	$891.2M+88.2%	$473.6M+408.8%	$93.1M
Cash & Equivalents	$799.6M+371.7%	$169.5M+30.6%	$129.8M+397.5%	$26.1M
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$67.5M+75.5%	$38.5M+32.5%	$29.1M-86.4%	$213.0M
Current Liabilities	$63.3M+75.7%	$36.0M+45.6%	$24.7M+90.2%	$13.0M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$1.5B+75.3%	$864.8M+90.9%	$453.0M+493.4%	-$115.1M
Retained Earnings	-$470.3M-42.9%	-$329.1M-59.3%	-$206.6M-76.6%	-$117.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.6B+90.3%	$832.2M+1.9%	$816.4M-5.8%	$866.5M-4.1%	$903.3M-3.2%	$933.2M-1.5%	$947.0M+107.1%	$457.2M
Current Assets	$1.6B+92.9%	$814.0M+1.8%	$799.3M-5.9%	$849.6M-4.7%	$891.2M-3.5%	$923.7M-1.5%	$937.6M+108.7%	$449.4M
Cash & Equivalents	$799.6M+677.0%	$102.9M-30.0%	$147.0M-3.4%	$152.1M-10.3%	$169.5M-1.5%	$172.1M-54.9%	$381.6M+290.1%	$97.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$67.5M+8.7%	$62.1M+40.1%	$44.4M+5.8%	$41.9M+8.9%	$38.5M+5.7%	$36.4M+40.1%	$26.0M-5.1%	$27.4M
Current Liabilities	$63.3M+10.0%	$57.5M+47.4%	$39.0M+7.0%	$36.5M+1.3%	$36.0M+7.7%	$33.4M+47.6%	$22.7M-3.9%	$23.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.5B+96.9%	$770.0M-0.3%	$772.1M-6.4%	$824.6M-4.6%	$864.8M-3.6%	$896.8M-2.6%	$921.0M+114.3%	$429.8M
Retained Earnings	-$470.3M+6.6%	-$503.3M-15.0%	-$437.6M-16.4%	-$375.9M-14.2%	-$329.1M-12.5%	-$292.6M-13.1%	-$258.6M-11.2%	-$232.6M

GPCR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$222.2M-90.5%	-$116.6M-46.7%	-$79.5M-72.4%	-$46.1M
Capital Expenditures	$3.6M+180.2%	$1.3M-40.5%	$2.2M+1298.1%	$155K
Free Cash Flow	-$225.8M-91.5%	-$117.9M-44.4%	-$81.7M-76.5%	-$46.3M
Investing Cash Flow	$89.8M+125.0%	-$358.9M-33.8%	-$268.3M-332.1%	-$62.1M
Financing Cash Flow	$762.5M+48.0%	$515.3M+14.1%	$451.5M+1456.3%	$29.0M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$64.4M-26.3%	-$51.0M+6.5%	-$54.6M-4.5%	-$52.2M-43.2%	-$36.5M-85.1%	-$19.7M+25.4%	-$26.4M+22.6%	-$34.1M
Capital Expenditures	$1.5M-4.8%	$1.6M+577.6%	$232K-26.1%	$314K+1862.5%	$16K-97.7%	$685K+60.4%	$427K+163.6%	$162K
Free Cash Flow	-$65.9M-25.4%	-$52.6M+4.1%	-$54.8M-4.3%	-$52.5M-44.0%	-$36.5M-79.0%	-$20.4M+24.0%	-$26.8M+21.7%	-$34.2M
Investing Cash Flow	$56.1M+213.8%	-$49.3M-200.8%	$48.9M+43.8%	$34.0M+2.4%	$33.2M+117.6%	-$189.0M+7.6%	-$204.5M-14522.8%	$1.4M
Financing Cash Flow	$705.0M+1154.4%	$56.2M+10771.0%	$517K-36.1%	$809K+31.5%	$615K+181.2%	-$757K-100.1%	$514.7M+73219.5%	$702K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GPCR Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	-9.3%+4.9pp	-14.2%+5.6pp	-19.8%	N/A
Return on Assets	-8.9%+4.7pp	-13.6%+5.0pp	-18.6%+33.9pp	-52.4%
Current Ratio	24.81+0.1	24.74+5.6	19.14+12.0	7.16
Debt-to-Equity	0.040.0	0.04-0.0	0.06+1.9	-1.85
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-8.5%-0.5pp	-8.0%-2.3pp	-5.7%	N/A	-3.8%-1.0pp	-2.8%+3.2pp	-6.1%
Return on Assets	N/A	-7.9%-0.4pp	-7.5%-2.1pp	-5.4%	N/A	-3.6%-0.9pp	-2.8%+2.9pp	-5.7%
Current Ratio	24.81+10.7	14.15-6.3	20.48-2.8	23.29-1.5	24.74-2.9	27.63-13.8	41.38+22.3	19.05
Debt-to-Equity	0.04-0.0	0.08+0.0	0.060.0	0.050.0	0.040.0	0.04+0.0	0.03-0.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Precigen Inc PGEN

$1.5B

Tourmaline Bio TRML

$1.2B

Enliven Therapeutics Inc ELVN

$2.3B

Nuvation Bio Inc NUVB

$1.5B

Amylyx Pharmaceuticals AMLX

$1.7B

Frequently Asked Questions

Is Structure Therapeutics Inc ADR profitable?

No, Structure Therapeutics Inc ADR (GPCR) reported a net income of -$141.2M in fiscal year 2025.

What is Structure Therapeutics Inc ADR's EBITDA?

Structure Therapeutics Inc ADR (GPCR) had EBITDA of -$175.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Structure Therapeutics Inc ADR's return on equity (ROE)?

Structure Therapeutics Inc ADR (GPCR) has a return on equity of -9.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Structure Therapeutics Inc ADR's free cash flow?

Structure Therapeutics Inc ADR (GPCR) generated -$225.8M in free cash flow during fiscal year 2025. This represents a -91.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Structure Therapeutics Inc ADR's operating cash flow?

Structure Therapeutics Inc ADR (GPCR) generated -$222.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Structure Therapeutics Inc ADR's total assets?

Structure Therapeutics Inc ADR (GPCR) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Structure Therapeutics Inc ADR's capital expenditures?

Structure Therapeutics Inc ADR (GPCR) invested $3.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Structure Therapeutics Inc ADR spend on research and development?

Structure Therapeutics Inc ADR (GPCR) invested $225.3M in research and development during fiscal year 2025.

How many shares does Structure Therapeutics Inc ADR have outstanding?

Structure Therapeutics Inc ADR (GPCR) had 213M shares outstanding as of fiscal year 2025.

What is Structure Therapeutics Inc ADR's current ratio?

Structure Therapeutics Inc ADR (GPCR) had a current ratio of 24.81 as of fiscal year 2025, which is generally considered healthy.

What is Structure Therapeutics Inc ADR's debt-to-equity ratio?

Structure Therapeutics Inc ADR (GPCR) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Structure Therapeutics Inc ADR's return on assets (ROA)?

Structure Therapeutics Inc ADR (GPCR) had a return on assets of -8.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Structure Therapeutics Inc ADR's cash runway?

Based on fiscal year 2025 data, Structure Therapeutics Inc ADR (GPCR) had $799.6M in cash against an annual operating cash burn of $222.2M. This gives an estimated cash runway of approximately 43 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Structure Therapeutics Inc ADR's Piotroski F-Score?

Structure Therapeutics Inc ADR (GPCR) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Structure Therapeutics Inc ADR's earnings high quality?

Structure Therapeutics Inc ADR (GPCR) has an earnings quality ratio of 1.57x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.